Home>>Signaling Pathways>> Apoptosis>> PAR4>>ML-354

ML-354 (Synonyms: VU0099704)

Catalog No.GC15710

PAR4 antagonist

Products are for research use only. Not for human use. We do not sell to patients.

ML-354 Chemical Structure

Cas No.: 89159-60-4

Size Price Stock Qty
1mg
$44.00
In stock
5mg
$121.00
In stock
10mg
$206.00
In stock
25mg
$484.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IC50: 140 nM

ML-354 is an indole-based, proteinase-activated receptor (PAR) 4 antagonist with good potency and reasonable selectivity versus PAR1. PARs are a family of four G-protein-coupled receptors GPCRs (PAR1-PAR4) with several unique attributes, which are activated by serine proteases. The activation of PARs needs a unique mechanism which requiring proteolysis unmasking their extracellular N-terminal domain. PAR4 is a thrombin receptor found on human platelets and represents a potential therapeutic target for the treatment of thrombotic disorders [1].

In vitro: Up to now, in vitro study of ML-354 is still in the development stage.

In vivo: Up to now, in vivo study of ML-354 is still in the development stage.

Reference:
[1].  Wen, W., Young, S., Duvernay, M., Schulte, M., Nance, K., & Melancon, B. et al. Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. Bioorganic & Medicinal Chemistry Letters. 2014; 24(19): 4708-4713.

Reviews

Review for ML-354

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ML-354

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.